Home  |  Contact

UniProtKB/Swiss-Prot Q9HCG7: Variant p.Arg873His

Non-lysosomal glucosylceramidase
Gene: GBA2
Variant information

Variant position:  873
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Arginine (R) to Histidine (H) at position 873 (R873H, p.Arg873His).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to medium size and polar (H)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In SPG46; loss of glucosylceramide catabolic process.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  873
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  927
The length of the canonical sequence.

Location on the sequence:   WERLGLAFQTPEAYCQQRVF  R SLAYMRPLSIWAMQLALQQQ
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 927 Non-lysosomal glucosylceramidase
Alternative sequence 836 – 927 GLTWEGFQTAEGCYRTVWERLGLAFQTPEAYCQQRVFRSLAYMRPLSIWAMQLALQQQQHKKASWPKVKQGTGLRTGPMFGPKEAMANLSPE -> LLPSGFCLWVIVISSTCWELLEGKDSTASIYPVEVALQRVPS. In isoform 2.


Literature citations

Lack of enzyme activity in GBA2 mutants associated with hereditary spastic paraplegia/cerebellar ataxia (SPG46).
Sultana S.; Reichbauer J.; Schuele R.; Mochel F.; Synofzik M.; van der Spoel A.C.;
Biochem. Biophys. Res. Commun. 465:35-40(2015)
Cited for: CHARACTERIZATION OF VARIANTS SPG46 121-TYR--GLU-927 DEL; 173-TRP--GLU-927 DEL; 234-ARG--GLU-927 DEL; 340-ARG--GLU-927 DEL; TRP-630 AND HIS-873; MUTAGENESIS OF PHE-419;

Mutations in GBA2 cause autosomal-recessive cerebellar ataxia with spasticity.
Hammer M.B.; Eleuch-Fayache G.; Schottlaender L.V.; Nehdi H.; Gibbs J.R.; Arepalli S.K.; Chong S.B.; Hernandez D.G.; Sailer A.; Liu G.; Mistry P.K.; Cai H.; Shrader G.; Sassi C.; Bouhlal Y.; Houlden H.; Hentati F.; Amouri R.; Singleton A.B.;
Am. J. Hum. Genet. 92:245-251(2013)
Cited for: VARIANTS SPG46 121-TYR--GLU-927 DEL; 340-ARG--GLU-927 DEL AND HIS-873;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.